The EHA Research Roadmap: Malignant Lymphoid Diseases

Normal Hematopoiesis; Malignant Lymphoid Malignant Myeloid Anemias and Related Diseases; Platelet Disorders; Blood Coagulation and Hemostatic Transfusion in Hematopoietic Stem Cell Transplantation; CAR-T and Other Cell- based Therapies; and analyze including immunother- apies will be increasingly implemented. These should improve the prognosis of high-risk patients but also significantly reduce treatment-related morbidity for patients of all ages, and especially for long-term survivors of childhood ALL. In addition, individualized drug dosing may prevent underdosing and hence may reduce the risk of relapse, while preventing over-dosing and associated toxic side effects. Other venues of development include ambitions to develop response adapted treatment strategies, based on MRD 66 ; incorporation of the new knowledge emerging from biology stud- ies into risk-based strategies, specifically targeting biological high-risk populations such as TP53-mutated MCL; strategies to improve outcome for BTKi-refractory disease; as well as real-world evidence studies, based on the high quality, nation-wide registers present in many European countries. supplemented with autologous serum against MALT lym- phoma of the conjunctiva. 115 Finally, first data of CAR-T-cell therapy for MZL were presented recently; assessment on a larger number of patients and longer follow-up is expected.